Molecular Formula | C10H11BO4 |
Molar Mass | 206.00294 |
In vitro study | AN3661 is active at nanomolar (IC 50 =20-56 nM) concentrations against P. falciparum laboratory strains known to be sensitive (3D7) or resistant (W2, Dd2, K1, HB3, FCR3 and TM90C2B), and AN3661 is similarly active in ex vivo studies of fresh Ugandan field isolates (mean ex vivo IC 50 =64 nM). AN3661 shows minimal cytotoxicity against mammalian cell lines, with the CC 50 60.5 μM against Jurkat cells, and all other CC 50 values greater than the highest concentrations tested (25 μM or above). AN3661 inhibits the stability of P. falciparum transcripts. |
In vivo study | AN3661 (50-200 mg.kg; p.o.; daily for 4 days) inhibits murine P. berghei infections with ED 90 (4 days) 0.34 mg/kg. AN3661 is administered orally for 4 days, beginning on the third day of infection, the ED 90 4 days after initiation of treatment is 0.57 mg/kg. Animal Model: P. berghei -infected mice (malaria model) Dosage: 50, 100, 200 mg/kg Administration: Orally; daily for 4 days Result: Rapidly controlled parasitemias, with an ED 90 of 0.34 mg/kg. Daily dosages of 50 mg/kg and 100 mg/kg extended survival, and mice treated with 200 mg/kg per day demonstrated long-term cures. |